Atossa Therapeutics(ATOS) - 2025 Q4 - Annual Results

Financial Position - As of December 31, 2025, Atossa Therapeutics, Inc. estimated cash and cash equivalents of approximately $40 million[6] - The financial results for the year ended December 31, 2025, are still subject to finalization and should not be solely relied upon[7] Development Strategy - The company is focusing on the development and regulatory strategy for (Z)-Endoxifen, with potential market opportunities being explored[10] Risks and Compliance - Forward-looking statements indicate potential risks and uncertainties related to clinical development timelines and regulatory approvals[11] - The company aims to regain and maintain compliance with Nasdaq listing requirements as part of its strategic objectives[11]